

DAFTAR PUSTAKA

- Ahmed H. Abdelhafiz, Siobhan H.M. Brown, Aminu Bello, Meguid El Nahas. (2010). Chronic Kidney Disease in Older People: Physiology, Pathology or Both?. *Nephron Clinical Practice*; 116 (1): c19–c24. <https://doi.org/10.1159/000314545>
- Alfano G, Perrone R, Fontana F, Ligabue G, Giovanella S, Ferrari A, Gregorini M, Cappelli G, Magistroni R, Donati G. (2022) Rethinking Chronic Kidney Disease in the Aging Population. *P* 12(11):1724.
- Ameer, O. Z. (2022). Hypertension in chronic kidney disease: What lies behind the scene. In *Frontiers in Pharmacology* (Vol. 13). Frontiers Media S.A. <https://doi.org/10.3389/fphar.2022.949260>
- Badro, D.A., (2023). Chronic Kidney Disease Management in Developing Countries. In: Al-Worafi, Y.M. (eds) *Handbook of Medical and Health Sciences in Developing Countries*. Springer, Cham.
- Banerjee T, Crews DC, and Wesson DE. (2017). CDC CKD Surveillance Team. Food insecurity, CKD, and subsequent ESRD in US adults. *Am J Kidney Dis.* 70(1):38-47.
- Bikbov B, Perico N, and Remuzzi G. (2018) "Disparities in Chronic Kidney Disease Prevalence among Males and Females in 195 Countries: Analysis of the Global Burden of Disease 2016 Study". *Nephron*. 139 (4): 313–318.Bülow RD, Boor P. Extracellular Matrix in Kidney Fibrosis: More Than Just a Scaffold. *J Histochem Cytochem*. 2019 Sep;67(9):643-661.
- Cheng Z, Zhang X, Zhang Y, Li L, Chen P. (2022) Role of MMP-2 and CD147 in kidney fibrosis. *Open Life Sci.* P 17(1):1182-1190. doi: 10.1515/biol-2022-0482. PMID: 36185410; PMCID: PMC9482425.
- Limbu MH, Wang Z, Liu J, Liu L, Zhang X, Chen P, Liu B., (2017). -2 and 9 in Chronic Kidney Disease. *Int J Mol Sci.* 18(4):776.
- f, D. W. & Gault, M. H., 1976. Prediction of creatinine clearance from



- serum creatinine. *Nephron* 16, 31–41
- De Bhailis ÁM, Kalra PA. Hypertension and the kidneys. *Br J Hosp Med (Lond)*. 2022 May 2;83(5):1-11. doi: 10.12968/hmed.2021.0440. Epub 2022 May 27
- Qazi M, Sawaf H, Ismail J, Qazi H, Vachharajani T. *EMJ Nephrol*. 2022;10[1]:102-113. DOI/10.33590/emjnephrol/22-00060.
- Garcia-Fernandez N, Jacobs-Cachá C, Mora-Gutiérrez JM, Vergara A, Orbe J, Soler MJ., 2020. Matrix Metalloproteinases in Diabetic Kidney Disease. *Journal of Clinical Medicine*. 2020; 9(2):472.
- GBD 2015 Disease and Injury Incidence and Prevalence, Collaborators. 2016. "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015". *Lancet*. 388 (10053): 1545–1602.
- Guillermo García, Arpana Iyengar, François Kaze, Ciara Kierans, Cesar Padilla-Altamira, Valerie A. Luyckx. Sex and gender differences in chronic kidney disease and access to care around the globe, *Seminars in Nephrology*, Volume 42, Issue 2, 2022, Pages 101-113, ISSN 0270-9295. <https://doi.org/10.1016/j.semephrol.2022.04.001>.
- Goldberg, I., & Krause, I. (2016). *THE ROLE OF GENDER IN CHRONIC KIDNEY DISEASE*. *EMJ*. 2016;1[2]:58-64. DOI/10.33590/emj/10312319.
- Gonzalez, J.; Mouttalib, S.; Delage, C.; Calise, D.; Maoret, J.J.; Pradère, J.P., 2013. Dual effect of chemokine CCL7/MCP-3 in the development of renal tubulointerstitial fibrosis. *Biochem. Biophys. Res. Commun.* 438, 257–263.
- Gultom, M. D., Korib Sudaryo, M., Studi, P., Epidemiologi, M., Epidemiologi, D., & Masyarakat, K. (n.d.). Hubungan Hipertensi dengan Kejadian Gagal Ginjal Kronik di RSUD DR. Djasamen Saragih Kota Pematang Siantar Tahun 2020.
- Mamile R, Hidayati P, Tenri Sanna A. (2022). Karakteristik Pasien dengan Gagal Ginjal Kronis di Rumah Sakit IbnuSina Makassar Tahun 2019-



2021. Wal'afiat Hospital Journal, Vol. 03 No. 02 (Desember, 2022): 126-138
E-ISSN 2722-9017

- Henriet P, Emonard H., (2019). Matrix metalloproteinase-2: Not (just) a "hero" of the past. *Biochimie*, 166: 223-232
- Hill NR, Fatoba ST, Oke JL, Hirst JA, O'Callaghan CA, Lasserson DS, Hobbs FD., 2016. Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. *PLoS One*. Jul 6;11(7)
- Itoh, Yoshifumi. (2015). Membrane-type Matrix Metalloproteinases: Their functions and regulations. *Matrix Biology*. 370.
- Katari S, Pasala C, Nalamolu R et al. (2019). Pathophysiology of matrix metalloproteinases in breast cancer progression. *Journal of Clinical and Scientific Research*, 8(3): 145-152.
- Kattah AG, Garovic VD. Understanding sex differences in progression and prognosis of chronic kidney disease. *Ann Transl Med*. 2020 Jul;8(14):897. doi: 10.21037/atm.2020.03.62.
- Kementerian Kesehatan InfoDATIN Pusat Data dan Informasi Kementerian Kesehatan RI. (2017). Situasi Penyakit Ginjal Kronis, pp. 1–10.
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease
- Kitty J. Jager, Csaba Kovesdy, Robyn Langham, Mark Rosenberg, Vivekanand Jha, Carmine Zoccali., 2019. A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases, *Kidney International*, Volume 96, Issue 5.
- Kobusiaak-Prokopowicz, Małgorzata, Krzysztofik, Justyna, Kaaz, Konrad, Jolda-Mydlowska, Beata and Mysiak, Andrzej. "MMP-2 and TIMP-2 in patients heart failure and chronic kidney disease" *Open Medicine*, vol. 13, no. 18, pp. 237-246. <https://doi.org/10.1515/med-2018-0037>
- CP., 2022. Epidemiology of chronic kidney disease: an update 2022.



- Kidney Int Suppl. Apr;12(1):7-11.
- Levey, A. S. et al., (2009). A new equation to estimate glomerular filtration rate. *Ann Intern Med* 150, 604–612.
- MacRae, C., Mercer, S. W., Guthrie, B., & Henderson, D. (2021). Comorbidity in chronic kidney disease: A large cross-sectional study of prevalence in Scottish primary care. *British Journal of General Practice*, 71(704), E243–E249. <https://doi.org/10.3399/bjgp20X714125>
- Manjunath, G., Sarnak, M. J. & Levey, A. S., (2001). Prediction equations to estimate glomerular filtration rate: an update. *Curr Opin Nephrol Hy* 10, 785–792.
- Meng, Xiao-Ming & Tang, Patrick & Li, Jun & Lan, Hui. (2015). TGF- β /Smad signaling in renal fibrosis. *Frontiers in physiology*. 6. 82.
- Meran, S.; Steadman, R., (2011). Fibroblasts and myofibroblasts in renal fibrosis. *Int. J. Exp. Pathol.*, 92, 158–167
- National Kidney Foundation. National Kidney Foundation, American Society for Clinical Pathology, leading laboratories and clinical laboratory societies unite to diagnose chronic kidney disease. <https://www.kidney.org/news/national-kidney-foundation-american-society-clinical-pathology-leading-laboratories-and>. Published February 21, 2018. Accessed August 13, 2019
- Pulido-Olmo, H., García-Prieto, C. F., Álvarez-Llamas, G., Barderas, M. G., Vivanco, F., Aranguez, I., Somoza, B., Segura, J., Kreutz, R., Fernández-Alfonso, M. S., Ruilope, L. M., & Ruiz-Hurtado, G., 2016. Role of matrix metalloproteinase-9 in chronic kidney disease: A new biomarker of resistant albuminuria. *Clinical Science*, 130(7), 525–538.
- Ren, J., Dai, C. (2020). Pathophysiology of Chronic Kidney Disease. In: Yang, J., He, W. (eds) *Chronic Kidney Disease*. Springer, Singapore.
- https://doi.org/10.1007/978-981-32-9131-7_2



as 2018., (2018). Depkes.go.id. 2018 Available from: /www.depkes.go.id/resources/download/info-terkini/hasil-risikesdas-.pd

- Salah, A., Alallam, A., Saad, A., Mohamed, A., Mohamed, M., Hassaan, M., Metwally, O. B., Raafat, L., Abdelghany, E., & Abdelaziem, O. M., (2022). Matrix Metalloproteinase 2 as a New Marker for Diagnosis of Chronic Kidney Disease. In *The Egyptian Journal of Hospital Medicine* (Vol. 87).
- Vaidya SR, Aedula NR. Chronic Renal Failure. [Updated 2022 Oct 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK535404/>
- Webster AC, Nagler EV, Morton RL, Masson P., (2017). Chronic Kidney Disease. Lancet. 25;389(10075):1238-1252.
- Yang, J., Dai, C., (2020). Pathophysiology of Chronic Kidney Disease. In: Yang, J., He, W. (eds) Chronic Kidney Disease. Springer, Singapore.

